Agios Pharmaceuticals Inc (AGIO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Brian M. Goff
Employees:
390
88 SIDNEY STREET, CAMBRIDGE, MA 02139
617-649-8600

Agios Pharmaceuticals, Inc. engages in the discovery and development of medicines in the field of cellular metaboli® and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes. AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.

Data derived from most recent annual or quarterly report
Market Cap 1.208 Billion Shares Outstanding55.739 Million Avg 30-day Volume 677.462 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.64
Price to Revenue141.0767 Debt to Equity0.0 EBITDA-383.925 Million
Price to Book Value1.5574 Operating Margin-3926.2717000000002 Enterprise Value508.751 Million
Current Ratio12.056 EPS Growth-0.684 Quick Ratio11.103
1 Yr BETA 1.2394 52-week High/Low 31.87 / 19.8 Profit Margin-3777.9571
Operating Cash Flow Growth11.5058 Free Cash Flow to Firm (FCFF) TTM -259.382 Million Free Cash Flow to Equity (FCFE) TTM
Altman Z-Score5.3918
View SEC Filings from AGIO instead.

View recent insider trading info

Agios Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding AGIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AGIO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-09-28 by JONES CECILIA
  • 4: filed on 2023-08-21 by BURNS JAMES WILLIAM
  • 4: filed on 2023-08-15 by BALLAL RAHUL D.
  • 4: filed on 2023-08-15 by SMITH CYNTHIA
  • 4: filed on 2023-08-10 by GOFF BRIAN
  • 4: filed on 2023-08-09 by WASHBURN THEODORE JAMES JR.
  • 4: filed on 2023-08-02 by WASHBURN THEODORE JAMES JR.
  • 4: filed on 2023-07-06 by GHEUENS SARAH
  • 4: filed on 2023-06-30 by BURNS JAMES WILLIAM
  • 4: filed on 2023-06-30 by GHEUENS SARAH

    • Events (8k)

  • 8-K: filed on 2023-11-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-14:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-25:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-19:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-03-03:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-23:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    JONES CECILIA CHIEF FINANCIAL OFFICER

    • Officer
    		 9,575 2023-09-26 3

    BURNS JAMES WILLIAM CHIEF LEGAL OFFICER

    • Officer
    		 23,890 2023-08-17 6

    SMITH CYNTHIA

    • Director
    		 2,302 2023-08-11 2

    BALLAL RAHUL D.

    • Director
    		 2,302 2023-08-11 2

    FOSTER-CHEEK KAYE I

    • Director
    		 13,724 2023-08-09 4

    GOFF BRIAN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 26,592 2023-08-08 3

    WASHBURN THEODORE JAMES JR. PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 2,741 2023-08-07 7

    GHEUENS SARAH CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-07-01 6

    FOUSE JACQUALYN A

    • Director
    		 106,966 2023-06-28 4

    MILANOVA TSVETA CHIEF COMMERCIAL OFFICER

    • Officer
    		 3,831 2023-06-28 3

    SCHENKEIN DAVID P

    • Director
    		 472,708 2023-06-21 9

    HO MAYKIN

    • Director
    		 11,524 2023-06-21 2

    SCADDEN DAVID

    • Director
    		 12,095 2023-06-21 2

    CAPELLO JEFFREY D

    • Director
    		 0 2023-06-13 2

    OWEN CATHERINE E.

    • Director
    		 0 2023-06-13 2

    MARAGANORE JOHN

    • Director
    		 28,528 2022-12-31 1

    PODDAR RICHA CHIEF COMMERCIAL OFFICER

    • Officer
    		 18,501 2022-10-15 0

    CLANCY PAUL J

    • Director
    		 34,282 2022-06-21 0

    CLARK IAN T

    • Director
    		 6,549 2022-05-20 0

    CAR BRUCE CHIEF SCIENTIFIC OFFICER

    • Officer
    		 52,500 2022-03-01 0

    BILLER JONATHAN CHIEF FINANCIAL OFFICER

    • Officer
    		 57,116 2022-02-18 0

    ALENSON CARMAN PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 3,555 2021-06-21 0

    BOWDEN CHRISTOPHER CHIEF MEDICAL OFFICER

    • Officer
    		 16,479 2021-06-18 0

    MILES DARRIN CHIEF COMMERCIAL OFFICER

    • Officer
    		 7,209 2021-05-14 0

    HIRSCH ANDREW CHIEF FINANCIAL OFFICER

    • Officer
    		 24,272 2020-04-22 0

    CELGENE CORP /DE/

    CELGENE EUROPEAN INVESTMENT CO LLC

    CELGENE SWITZERLAND LLC

    CELGENE ALPINE INVESTMENT CO., LLC

    • 10% Owner
    		 7,121,658 2019-11-12 0

    BILLER SCOTT CHIEF SCIENTIFIC OFFICER

    • Officer
    		 86,788 2019-06-11 0

    HOERTER STEVEN L. CHIEF COMMERCIAL OFFICER

    • Officer
    		 10,941 2019-03-01 0

    CANTLEY LEWIS CLAYTON JR.

    • Director
    		 200,596 2017-12-06 0

    NELSEN ROBERT

    • Director
    		 109,230 2017-03-03 0

    COLE DOUGLAS G.

    • Director
    		 2,778 2016-08-10 0

    TESSIER-LAVIGNE MARC

    • Director
    		 0 2016-06-21 0

    GODDARD GLENN SENIOR VICE PRESIDENT, FINANCE

    • Officer
    		 0 2016-02-16 0

    HIGGONS JOHN DUNCAN CHIEF OPERATING OFFICER

    • Officer
    		 120,834 2016-01-04 0

    KARSEN PERRY A

    • Director
    		 0 2015-06-23 0

    STARR KEVIN P

    • Director
    • 10% Owner
    		 184,386 2015-02-19 0

    ARCH VENTURE FUND VII LP

    ARCH VENTURE PARTNERS VII, L.P.

    ARCH VENTURE PARTNERS VII, LLC

    CRANDELL KEITH

    BYBEE CLINTON

    • 10% Owner
    		 No longer subject to file 2015-02-19 0

    THIRD ROCK VENTURES LP

    THIRD ROCK VENTURES GP, L.P.

    TRV GP, LLC

    • 10% Owner
    		 No longer subject to file 2015-02-19 0

    CELGENE EUROPEAN INVESTMENT CO LLC

    • 10% Owner
    		 5,242,704 2014-12-16 0

    FLAGSHIP VENTURES FUND 2007, L.P.

    AFEYAN NOUBAR

    KANIA EDWIN M JR

    FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC

    • 10% Owner
    		 No longer subject to file 2014-06-23 0

    CELGENE EUROPEAN INVESTMENT CO LLC

    CELGENE CORP /DE/

    CELGENE ALPINE INVESTMENT CO., LLC

    • 10% Owner
    		 5,014,059 2014-04-29 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 22:15:04 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 21:45:03 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 21:15:04 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 20:45:04 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 20:15:04 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 19:45:03 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 19:15:04 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 18:45:03 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 18:15:03 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 17:45:04 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 17:15:04 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 16:45:04 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 16:15:04 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 15:45:03 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 15:15:03 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 14:45:04 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 14:15:04 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 13:45:04 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 13:15:03 UTC 4.9047 0.4153 2500000
    AGIOS PHARMACEUTICALS INC AGIO 2023-11-28 12:45:04 UTC 4.9047 0.4153 2500000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund AGIO -66.0 shares, $-2310.0 2020-09-30 N-PORT
    AQR Funds- AQR Large Cap Relaxed Constraint Equity Fund AGIO -598.0 shares, $-19375.2 2019-09-30 N-PORT
    FundVantage Trust- Gotham Master Neutral Fund AGIO -19.0 shares, $-665.0 2020-09-30 N-PORT
    FundVantage Trust- Gotham Hedged Plus Fund AGIO -119.0 shares, $-3341.52 2022-12-30 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund AGIO -2700.0 shares, $-66825.0 2023-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments